These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19499565)

  • 1. Effect of route of administration of human recombinant factor VIII on its immunogenicity in Hemophilia A mice.
    Peng A; Gaitonde P; Kosloski MP; Miclea RD; Varma P; Balu-Iyer SV
    J Pharm Sci; 2009 Dec; 98(12):4480-4. PubMed ID: 19499565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII.
    Kosloski MP; Miclea RD; Balu-Iyer SV
    AAPS J; 2009 Sep; 11(3):424-31. PubMed ID: 19499345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative immunogenicity of recombinant B domain-deleted porcine factor VIII and Hyate:C in hemophilia A mice presensitized to human factor VIII.
    Parker ET; Craddock HN; Barrow RT; Lollar P
    J Thromb Haemost; 2004 Apr; 2(4):605-11. PubMed ID: 15102015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical characterization and immunogenicity of Neureight, a recombinant full-length factor VIII produced by fed-batch process in disposable bioreactors.
    Delignat S; Peyron I; El Ghazaly M; V Kaveri S; Rohde J; Mueller F; Lacroix-Desmazes S
    Cell Immunol; 2018 Sep; 331():22-29. PubMed ID: 29751951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex.
    Purohit VS; Ramani K; Sarkar R; Kazazian HH; Balasubramanian SV
    J Biol Chem; 2005 May; 280(18):17593-600. PubMed ID: 15728582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice.
    Peng A; Straubinger RM; Balu-Iyer SV
    AAPS J; 2010 Sep; 12(3):473-81. PubMed ID: 20517659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model.
    Batsuli G; Ito J; Mercer R; Baldwin WH; Cox C; Parker ET; Healey JF; Lollar P; Meeks SL
    J Thromb Haemost; 2018 Sep; 16(9):1779-1788. PubMed ID: 29981270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-linked glycosylation modulates the immunogenicity of recombinant human factor VIII in hemophilia A mice.
    Lai JD; Swystun LL; Cartier D; Nesbitt K; Zhang C; Hough C; Dennis JW; Lillicrap D
    Haematologica; 2018 Nov; 103(11):1925-1936. PubMed ID: 30002126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. O-phospho-L-serine, multi-functional excipient for B domain deleted recombinant factor VIII.
    Miclea RD; Purohit VS; Balu-Iyer SV
    AAPS J; 2007 Jun; 9(2):E251-9. PubMed ID: 17907766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The humoral response to human factor VIII in hemophilia A mice.
    Healey JF; Parker ET; Barrow RT; Langley TJ; Church WR; Lollar P
    J Thromb Haemost; 2007 Mar; 5(3):512-9. PubMed ID: 17181826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of immune tolerance by neonatal intravenous injection of human factor VIII in murine hemophilia A.
    Madoiwa S; Yamauchi T; Hakamata Y; Kobayashi E; Arai M; Sugo T; Mimuro J; Sakata Y
    J Thromb Haemost; 2004 May; 2(5):754-62. PubMed ID: 15099282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidation of factor VIII increases its immunogenicity in mice with severe hemophilia A.
    Peyron I; Dimitrov JD; Delignat S; Gangadharan B; Srivastava A; Kaveri SV; Lacroix-Desmazes S
    Cell Immunol; 2018 Mar; 325():64-68. PubMed ID: 29395036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene.
    Chao BN; Baldwin WH; Healey JF; Parker ET; Shafer-Weaver K; Cox C; Jiang P; Kanellopoulou C; Lollar P; Meeks SL; Lenardo MJ
    J Thromb Haemost; 2016 Feb; 14(2):346-55. PubMed ID: 26588198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01/2010 study.
    Werwitzke S; Geisen U; Nowak-Göttl U; Eichler H; Stephan B; Scholz U; Holstein K; Klamroth R; Knöbl P; Huth-Kühne A; Bomke B; Tiede A
    J Thromb Haemost; 2016 May; 14(5):940-7. PubMed ID: 26988717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A.
    Ramani K; Miclea RD; Purohit VS; Mager DE; Straubinger RM; Balu-Iyer SV
    J Pharm Sci; 2008 Apr; 97(4):1386-98. PubMed ID: 17705286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a mice.
    Pisal DS; Kosloski MP; Middaugh CR; Bankert RB; Balu-Iyer SV
    J Pharm Sci; 2012 Jun; 101(6):2055-65. PubMed ID: 22388918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous administration of Factor VIII-O-Phospho-L-Serine (OPLS) complex reduces immunogenicity and preserves pharmacokinetics of the therapeutic protein.
    Gaitonde P; Purohit VS; Balu-Iyer SV
    Eur J Pharm Sci; 2015 Jan; 66():157-62. PubMed ID: 25459532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors.
    Zakas PM; Vanijcharoenkarn K; Markovitz RC; Meeks SL; Doering CB
    J Thromb Haemost; 2015 Jan; 13(1):72-81. PubMed ID: 25315236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia A mice.
    Peng A; Kosloski MP; Nakamura G; Ding H; Balu-Iyer SV
    AAPS J; 2012 Mar; 14(1):35-42. PubMed ID: 22173945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonhuman glycans can regulate anti-factor VIII antibody formation in mice.
    Arthur CM; Zerra PE; Shin S; Wang J; Song X; Doering CB; Lollar P; Meeks S; Stowell SR
    Blood; 2022 Mar; 139(9):1312-1317. PubMed ID: 34019619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.